Journal Article

A common haplotype of the annexin A5 (<i>ANXA5</i>) gene promoter is associated with recurrent pregnancy loss

Nadia Bogdanova, Jürgen Horst, Marcin Chlystun, Peter J.P. Croucher, Almut Nebel, Axel Bohring, Albena Todorova, Stefan Schreiber, Volker Gerke, Michael Krawczak and Arseni Markoff

in Human Molecular Genetics

Volume 16, issue 5, pages 573-578
Published in print March 2007 | ISSN: 0964-6906
Published online March 2007 | e-ISSN: 1460-2083 | DOI: http://dx.doi.org/10.1093/hmg/ddm017
A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss

Show Summary Details

Preview

We sought to verify whether variation in the promoter of the gene encoding placental anticoagulant protein annexin A5 (ANXA5) represents a risk factor for recurrent pregnancy loss (RPL). Sequence analysis of 70 German RPL patients, all known to carry neither factor V Leiden nor a prothrombin mutation, revealed four consecutive nucleotide substitutions in the ANXA5 promoter, which were transmitted as a joint haplotype (M2). Reporter gene assays revealed that M2 reduces the in vitro activity of the ANXA5 promoter to 37–42% of the normal level. The possible relationship between M2 and RPL was evaluated by comparing RPL patients with two independent control groups recruited from the registry of the Institut für Humangenetik in Münster and the PopGen biobank in Kiel, respectively. Carriers of M2 were found to exhibit a > 2-fold higher RPL risk than non-carriers (odds ratio, 2.42; 95% confidence interval, 1.27–4.58) when using unselected controls (PopGen) and an almost 4-fold higher risk when using the Münster ‘super-controls’, i.e. women with successful pregnancies and no previous history of pregnancy losses (odds ratio, 3.88; 95% confidence interval, 1.98–7.54). This statistically significant association should facilitate the development of improved prognostic algorithms for RPL, involving a more precise assessment of individual disease risks, and provide a guide to offering adequate therapies where relevant.

Journal Article.  3936 words.  Illustrated.

Subjects: Genetics and Genomics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.